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Abstract
Background: Fingolimod (FTY720), the first oral treatment for multiple sclerosis (MS), blocks immune cell trafficking
and prevents disease relapses by downregulation of sphingosine-1-phosphate receptor. We determined the effect
of FTY720 on human T cell activation and effector function.
Methods: T cells from MS patients and healthy controls were isolated to measure gene expression profiles in
the presence or absence of FTY720 using nanostring and quantitative real-time polymerase chain reaction (qPCR).
Cytokine protein expression was measured using luminex assay and flow cytometry analysis. Lentivirus vector
carrying short hairpin RNA (shRNA) was used to knock down the expression of specific genes in CD4+ T cells.
Chromatin immunoprecipitation was performed to assess T cell factor 1 (TCF-1) binding to promoter regions.
Luciferase assays were performed to test the direct regulation of interferon gamma (IFN-γ) and granzyme B
(GZMB) by TCF-1. Western blot analysis was used to assess the phosphorylation status of Akt and GSK3β.
Results: We showed that FTY720 treatment not only affects T cell trafficking but also T cell activation. Patients
treated with FTY720 showed a significant reduction in circulating CD4 T cells. Activation of T cells in presence of
FTY720 showed a less inflammatory phenotype with reduced production of IFN-γ and GZMB. This decreased
effector phenotype of FTY720-treated T cells was dependent on the upregulation of TCF-1. FTY720-induced TCF-1
downregulated the pathogenic cytokines IFN-γ and GZMB by binding to their promoter/enhancer regions and
mediating epigenetic modifications. Furthermore, we observed that TCF-1 expression was lower in T cells from
multiple sclerosis patients than in those from healthy individuals, and FTY720 treatment increased TCF-1 expression
in multiple sclerosis patients.
Conclusions: These results reveal a previously unknown mechanism of the effect of FTY720 on human CD4+ T cell
modulation in multiple sclerosis and demonstrate the role of TCF-1 in human T cell activation and effector function.
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Background
Multiple sclerosis is a chronic inflammatory disorder of the
central nervous system (CNS) driven by autoreactive lym-
phocytes that induce an inflammatory cascade leading to
damage of myelin and axon, resulting in neurodegeneration
[1]. In particular, T cells that produce pro-inflammatory
cytokines such as interferon gamma (IFN-γ) and interleukin
(IL)-17 play a critical role in multiple sclerosis pathogenesis
[1–8], and reduced levels of these effector molecules are
associated with better therapeutic responses [9–11]. Al-
though the expression of granzyme B (GZMB) is linked to
the pathogenic signature of T cells in experimental auto-
immune encephalomyelitis (EAE) [12] and multiple scler-
osis [13], its precise role in multiple sclerosis is still under
investigation.
Fingolimod (FTY720), a sphingosine 1-phosphate (S1P)
receptor modulator, was approved as the first oral treat-
ment for multiple sclerosis based on results of three separ-
ate clinical trials among patients with relapsing-remitting
multiple sclerosis (RRMS) [14–16]. S1P receptors are
highly expressed on membranes of lymphocytes and are
critical for T and B cell egress from secondary lymphoid
organs. The phosphorylated form of FTY720 causes in-
ternalization and degradation of S1P receptors, resulting
in the retention of lymphocytes in lymph nodes [17].
FTY720 primarily reduces the number of naïve T cells and
central memory T cells in the circulation due to their
expression of homing receptor CCR7 [18].
T cell factor 1 (TCF-1), also known as TCF7 (gene name),
is a transcription factor present in hematopoietic T cells
that has an important function in T cell development in the
thymus. TCF-1 negatively regulates Th1 [19] and Th17 [20,
21] differentiation while promoting Th2 differentiation, via
stimulation of GATA3 (a Th2-specific transcription factor)
[19]. TCF7 knock-out mice are susceptible to EAE [20] and
develop aggressive T cell deficiencies resembling human T
cell acute lymphoblastic leukemia [22]. Interestingly, a com-
putational re-analysis of multiple sclerosis-associated single
nucleotide polymorphism data from 112 different cell types
suggests that TCF7 is associated with multiple sclerosis
[23], and a recent genome-wide association study identified
the single nucleotide polymorphism rs756699 located on
the TCF7 gene in multiple sclerosis patients [24]. However,
the role of TCF-1 in the regulation of human CD4+ T cell
effector function and its relevance to multiple sclerosis and
treatment response are unknown.
In this study, we found that FTY720 modulates CD4+ T
cell activation and effector function through TCF-1.
FTY720-induced TCF-1 regulates the expression of IFN-γ
and GZMB in T cells. Furthermore, T cells from multiple
sclerosis patients exhibit lower TCF7 expression than
those from healthy individuals, and FTY720 treatment
upregulates TCF7 expression in T cells from both healthy
controls and patients. Our findings establish that TCF-1
expression in human CD4+ T cells is linked to multiple
sclerosis and that treatment with FTY720 increases TCF-1
expression, which regulates IFN-γ and GZMB production.
Methods
Subjects and blood samples
Peripheral venous blood was collected after obtaining
informed consent from healthy individuals and multiple
sclerosis patients. All patients were seen at the Partners
Multiple Sclerosis Center at Brigham and Women’s
Hospital. We included untreated RR multiple sclerosis
patients and patients treated with FTY720 before and
after 3 months of treatment. Patients were classified
based upon their clinical characteristics as defined by
2010 Revisions to the McDonald Criteria [25] with the
help of trained neurologists. Untreated multiple sclerosis
patients had received no treatment with glatiramer acetate
or interferons in the past 3 months, no treatment with
other disease-modifying therapy in the past 6 months, and
no steroids in the past month. Detailed characteristics of
these patients are shown in Additional file 1: Table S1.
Blood samples were collected under the Comprehensive
Longitudinal Investigation of Multiple Sclerosis at Brig-
ham and Women’s Hospital (CLIMB). This study was
conducted in accordance with the WMA Declaration of
Helsinki regarding ethical principles for medical research
involving human subjects. The Partners Human Research
Committee/Instutional Review Board approved the use of
human material (IRB protocols 1999P010435/BWH and
2012P000394).
Naïve CD4+ T cell isolation, culture, and flow cytometry
analysis
Peripheral blood mononuclear cells (PBMCs) were isolated
by Ficoll-Hypaque density gradient centrifugation (Pharma-
cia LKB Biotechnology, Piscataway, NJ). Naïve T cells from
PBMCs were isolated using a Miltenyi Biotec (Alburn, CA)
negative selection kit. Purified naïve CD4+ T cells were
activated with plate-bound anti-CD3 (5 μg/ml, BD Bio-
science, San Jose CA), soluble anti-human CD28 (1 μg/ml,
BD Bioscience), and IL-2 (20 ng/ml, R&D Systems) with or
without FTY720 (100 ng/ml, Novartis). After 6 days, cell-
free culture supernatants were collected for cytokine
analysis by Luminex assay (Miltenyi Biotec), and cells were
harvested for RNA extraction and intracellular staining.
Naïve T cells were stimulated with PMA (Sigma), ionomy-
cin (Sigma), and Golgistop for 4 h. Cells were stained for
anti-human CD4 APC (BD Bioscience) and violet fluores-
cent reactive dye VVD (Life Technologies), and then cells
were fixed and permeabilized with BD fixation and
permeabilization buffer and stained for IFN-γ FITC and
GZMB FITC (BD Bioscience). For surface staining, the fol-
lowing antibodies were used: anti-human CD4 pacific blue,
anti-human CCR7 PE, and anti-human CD45RA APC,
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IgG2a PE isotype control, IgG2b, and k APC isotype con-
trol (all from BD Bioscience). All antibodies were titrated
for flow cytometry, which was performed on a BD LSR II
(BD Bioscience) and analyzed using Flowjo software.
Nanostring and quantification by real-time PCR
Total RNA was isolated from cultured T cells using RNA
isolation kit (Norgen Biotek). RNA expression of 500
immune genes was detected by NanoString array (nCoun-
ter, Gene expression code set, Human Immunology Kit).
Experiment was performed and analyzed following the
manufacturers’ instructions. Data were normalized to
spiked positive controls and housekeeping genes (nSolver
Analysis system). Results from NanoString arrays were
validated using Taqman PCR (Life Technologies). Briefly,
first-strand cDNA synthesis was performed for each RNA
sample from 0.5 to 1 μg of total RNA using Taqman re-
verse transcription reagents (Applied Biosystems). Quanti-
tative real-time polymerase chain reaction (qPCR) was
performed using primers for TCF-7 (Hs00175273_m1),
IFNG (Hs99999041_m1), and GZMB (Hs001554355_m1)
and the housekeeping genes GAPDH (Hs02758991_g1),
G6PD (Hs00166169_m1), GUSB (Hs00939627_m1), TPB
(Hs00427620_m1), TUBB (Hs00742828_s1), POLR1B
(Hs00219263_m1), POLR2A (Hs00172187_m1), HPRT1
(Hs02800695_m1), PRL19 (Hs02338565_gH), EEFG1
(Hs01922638_u1), ALAS1 (Hs00963534_m1), and OAZ1
(Hs00427927_m1) with TaqMan Fast Universal qPCR
Master Mix (No ampErase Uracil N-Glycosylase, Life
Technologies). Samples were run on QuantStudio 7 (Ap-
plied Biosystems, Life Technologies). The mean of the 12
housekeeping genes was used as an endogenous control to
normalize total cDNA for each sample, and all values are
shown as relative expression.
In vitro knockdown with shRNA
The expression of TCF-1 was knocked down in primary
naïve CD4+ Tcells by lentivirus vector carrying short hair-
pin RNA (shRNA) against TCF-1 (mission shRNA bacter-
ial glycerol stock TRCN0000281336, Sigma-Aldrich) or a
non-targeting sequence (a gift from Dr. Thomas Pertel at
BWH and Dr. David Root at Broad Institute) as a control.
Primary naïve CD4+ T cells were cultured in a 24-well
plate in the presence of anti-CD3, anti-CD28, and IL2 and
incubated with lentivirus. After 3 days, the lentivirus was
washed away, and puromycin was added (1.5 μg/ml) to
select transduced T cells for 3 days. Live cells were sorted
using intracellular fluorescence-activated cell sorting, and
the expression of TCF-1 was measured using qPCR.
Chromatine immune precipitation assay
The binding of TCF-1, H3-Lys9, and H3-Lys27 on
IFNG and GZMB were analyzed using chromatin im-
munoprecipitation (ChIP) assay as described previously
[26, 27]. The antibodies used for ChIP assay were anti-
TCF-1 (Cell Signaling), anti-trimethyl-histone H3-Lys9
(Millipore), and anti-trimethyl-histone H3-Lys27 anti-
bodies (Millipore) or Rabbit IgG (Millipore). Input
DNA and DNA recovered after immunoprecipitation
were analyzed by real-time qPCR using primer pairs for
IFNG and GZMB (IFNG: forward 5′-GAAGAGTCAA-
CATTTTACCAGGGC and reverse 5′-GTGACAGA-
TAGGCAGGGATGATAG; GMZB: forward 5′-GAACC
TGGTGCAATTACCAGAAT and reverse 5′CTTTTCA
CAGGGATAAACTGCTGG) with SyBR green Fast
Master mix (Applied Biosystems). Values for TCF-1 bind-
ing with IFNG promoter and GZMB enhancer regions
were normalized to IgG.
Luciferase reporter assay
HEK293T cells were maintained in DMEM medium
(Gibco) supplemented with 10 % fetal bovine serum
(Gibco), 4 mM L-glutamine (Lonza), 1 mM sodium pyru-
vate (Lonza), 1 % non-essential amino acid (Lonza), and
10 mM HEPES (Lonza) at 37 °C/5 % CO2. Forty-eight
hours prior to transfection, cells were seeded at 10,000
cells per well in a 96-well tissue culture plate (Perkin
Elmer). Cells were transfected with the indicated amounts
of each expression vector using Lipofectamine 2000 (Invi-
trogen) following the manufacturer’s instructions. Renilla
luciferase vector (12.5 ng) was used for normalization of
transfection efficiency. Forty-eight hours after transfec-
tion, cells were assayed using the Dual-Luciferase Reporter
Assay System kit (Promega) as per the manufacturer’s
instructions. Firefly luciferase values were normalized to
Renilla luciferase levels. The results were expressed as
relative luciferase activity in relative light units (RLU).
Transfections were carried out in triplicate in three inde-
pendent experiments, and results are expressed as mean
± standard error.
Plasmids
The −3.6-kb human IFNG-luc in a pGL3 vector back-
ground was a gift from Howard Young (Addgene plasmid
#17599) [28], pcDNA3-HA-TCF1 was a gift from Kai Ge
(Addgene plasmid #40620) [29], plasmid encoding Tbet
was a gift from Dr. Christine Campbell [30], 1436 pcDNA3
Flag HA was a gift from William Sellers (Addgene plasmid
#10792), and pGL3 basic and pGL3 promoter vector were
purchased from Promega. A 1.04-kb fragment of the hu-
man GZMB enhancer region was inserted as three repeats
between KpnI and NheI sites into the pGL3 promoter
vector to generate the GZMB-luc plasmid (GenScript).
Western blot
Naïve T cells were isolated from PBMCs, activated in the
presence or absence of FTY720, and collected after 15,
30, 60, or 120 min. Cells were lysed with RIPA assay
Mazzola et al. Journal of Neuroinflammation  (2015) 12:245 Page 3 of 12
buffer (Thermo Scientific) supplemented with protease
and phosphatase inhibitors (Thermo Scientific). Total
protein concentration was determined by BCA assay
(Thermo Scientific). Samples were prepared with 20 μg
of protein, loading buffer (Life Technologies), and redu-
cing agent (Life Technologies) and then heated for
10 min at 70 °C before use. Samples were run on a 10 %
bis-tris gel (NOVO, Life Technologies), transferred to
PVDF membrane, and detected by immunoblot. The
following antibodies were used: p-AKT (Cell Signaling
Technology), p-GSK3β (Cell Signaling Technology),
pan-AKT (Cell Signaling Technology), pan-GSK3β (Cell
Signaling Technology), beta actin (Cell Signaling Tech-
nology), and anti-rabbit IgG HRP (Cell Signaling Tech-
nology). The membrane was blocked with 5 % bovine
serum albumin followed by primary and secondary anti-
body incubations as per the manufacturers’ instructions.
Immunoblots were developed using ECL Prime (GE
Healthcare).
Statistical analysis
All statistical analyses were performed using GraphPad
Prism software. Paired and unpaired non-parametric t tests
were used to test for group differences. Correlations were
calculated using Spearman’s rank correlation coefficient.
Results
FTY720 treatment decreases circulating CD4+ T cells and
increases TCF7 expression in CD4+ T cells.
FTY720 decreases relapses in multiple sclerosis, and its
therapeutic effects are attributed to the sequestration of
lymphocytes into the lymph nodes [18]. We character-
ized the frequency of total and naïve CD4+ T cells in
multiple sclerosis patients before and 3 months after
FTY720 treatment. Consistent with previous observa-
tion, [18] FTY720 treatment reduced the percentage and
absolute number of circulating total CD4+ (Additional
file 2: Figure S1 A and C) and naïve CD4+ T cells (Add-
itional file 2: Figure S1 B and D), 3 months after treat-
ment relative to baseline measurements. FTY720-treated
patients continue to generate an immune response
against foreign antigens indicating that the T cells still
have the ability to egress from lymph nodes and poten-
tially impact the CNS [31]. To further define the impact
of FTY720 on immune cell function, we assessed the ef-
fect of FTY720 treatment on CD4+ T cell effector
function.
Purified naïve T cells from healthy individuals were
activated in the presence or absence of FTY720 at con-
centration of 100 ng/ml. Although the physiological con-
centration of FTY720 in blood is in a range of 5 to
10 ng/ml [18, 32], the concentration of the lymph nodes
is 10 times higher [33]. Since we wanted to recapitulate
the physiological effect of FTY720 on T cell activation
within the lymph nodes, we chose to use the concentration
of 100 ng/ml. We measured the effect of FTY720 on T cell-
associated immune gene expression using nanostring-based
immune arrays. We found that FTY720-treated T (T-
FTY720) cells had a distinct immune gene signature, with
33 upregulated genes and 24 downregulated genes relative
to untreated T (T-CTL) cells (Fig. 1a). We selected TCF7
based upon its relevance shown by several studies
highlighting its role on T cell differentiation in mice and in
EAE induction. In addition, recent observations in GWAS
studies have correlated TCF7 with MS pathogenesis. These
studies, however, did not address the functional role of
TCF7 in MS patients, thus, we focused our attention on
TCF7. We found that T-FTY720 cells showed greater
TCF7 expression than T-CTL cells (Fig. 1b). These results
were further confirmed by qPCR, which also showed in-
crease in the expression of TCF7 in T-FTY720 compared
to T-CTL (Fig. 1c). To determine whether this increase in
TCF7 expression was specifically brought about by
FTY720, we activated T cells in the presence of other ap-
proved drugs for multiple sclerosis treatment, namely inter-
feron beta and natalizumab. We found increased
expression of TCF7 only in T-FTY720 cells but not T cells
treated with interferon beta (T-IFN beta) or natalizumab
(T-Ty) (Additional file 3: Figure S2), suggesting that expres-
sion of TCF7 is specifically enhanced upon FTY720
treatment.
FTY720 treatment decreases effector T cell function
To investigate whether FTY720 modulates effector
function of CD4+ T cells, we measured cytokine ex-
pression in naïve CD4+ T cells treated with or with-
out FTY720. We observed that, compared to T-CTL
cells, T-FTY720 cells showed lower messenger RNA
(mRNA) expression of IFNG and GZMB as measured
by nanostring array (Fig. 2a) and qPCR (Fig. 2b) and
lower protein expression of IFN-γ and GZMB as
measured by Luminex-based assay (Fig. 2c) and intra-
cellular fluorescence-activated cell sorting analysis
(Fig. 2d).
In addition to IFN-γ and GZMB expressions, we mea-
sured the expression of pro-inflammatory cytokines IL-
17, granulocyte macrophage colony-stimulating factor
(GMCSF), and tumor necrosis factor alpha (TNF-α) in
supernatant collected from T-FTY720 and T-CTL cells
using Luminex-based assay. We found decreased expres-
sion of IL-17, GMCSF, and TNF-α in T-FTY720 cells
compared to T-CTL cells (Additional file 4: Figure S3
A). To determine whether this decreased cytokine pro-
duction was related to excessive cell death, we measured
the percentage of dead cells in T cell cultures in the pres-
ence or absence of FTY720. We found no difference in
the percentage of dead T cells between groups (Additional
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file 4: Figure S3 B), suggesting that the effect of FTY720 is
not mediated by increased cell death.
TCF-1 regulates IFN-γ and GZMB expression
TCF-1 regulates T cell development and differentiation in
mice [19–21, 34–36]. However, the role of TCF-1 in the
regulation of CD4+ T cell function in humans remains
unclear. Therefore, we analyzed the transcriptional regula-
tion of IFNG and GZMB in CD4+ T cells by TCF-1 upon
FTY720 treatment. We performed an in silico analysis
and found that TCF-1 has binding sites in the IFNG pro-
moter (−321 to −85 bp) and GZMB enhancer (+1606 to
+1841 bp) regions (Fig. 3a). Using chromatin immunopre-
cipitation (ChIP) assay, we found increased binding of
TCF-1 on both IFNG promoter and GZMB enhancer
regions in FTY720-treated cells (Fig. 3b).
Regulation of IFN-γ and GZMB expression by TCF-1
was investigated by knockdown of TCF7 expression
using lentivirus particles carrying shRNA against TCF7
or negative control. We found that shRNA-mediated
knockdown of TCF7 (Fig. 3c) resulted in an increased
IFNG and GZMB expression in T cells suggesting that
TCF-1 might directly affect IFNG and GZMB expres-
sion (Fig. 3d).
Fig. 1 FTY720 treatment increases TCF7 expression in T cells. a Heatmap showing significantly changing mRNA expression upon CD4 naïve T cell
activation in the presence or absence of FTY720 as measured by a nanostring array of 500 immune genes. b Expression of TCF7 in in vitro activated T cells
from healthy control (HC) individuals in the presence (T-FTY720) or absence (T-CTL) of FTY720 analyzed using nanostring (n= 6). c Expression of TCF7 in in
vitro activated T cells from HC individuals in the presence or absence of FTY720 analyzed using qPCR (n= 10). **p< 0.01, paired non-parametric t tests
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Next, we performed a dual-luciferase reporter assay in
HEK293T cells to determine whether TCF-1 directly re-
presses IFN-γ and GZMB expression by binding to their
promoter and enhancer regions, respectively. We used a
plasmid encoding firefly luciferase downstream of the IFNG
promoter region (IFNG-luc) that included the putative
TCF-1 binding site determined by the ChIP assay as well as
a binding site for Tbet, a transcription factor that reportedly
activates IFN-γ expression [30, 37, 38]. We found increased
relative firefly luciferase levels in cells co-transfected with
IFNG-luc and Tbet expression plasmid compared with cells
transfected with an empty vector. However, cells co-
transfected with TCF-1 expression plasmid and IFNG-luc
did not induce luciferase reporter activity; however, when
both Tbet and TCF-1 expression plasmids were co-
transfected with IFNG-luc, Tbet-induced firefly luciferase
activity was reduced in a TCF-1 dose-dependent manner
(Fig. 3e), suggesting that TCF-1 represses transcription at
the IFNG promoter. We used a reporter plasmid containing
the 1.04-kb GZMB enhancer sequence identified from our
ChIP assay at a site upstream of the SV40 promoter that
regulates firefly luciferase (GZMB-luc). We observed that
firefly luciferase activity decreased significantly when
HEK293T cells were co-transfected with GZMB-luc and in-
creasing amounts of the TCF-1 expression plasmid (Fig. 3f).
Firefly luciferase activity was unchanged in cells co-
transfected with GZMB-luc reporter plasmid and an empty
vector suggesting that repression of luciferase activity was
TCF-1 dependent.
Using in silico analysis, we observed that TCF-1 also has
putative binding sites in TNF-α, IL-17, and CSF2 pro-
moters (Additional file 4: Figure S3 C). However, we did
not observe the binding of TCF-1 to CSF2 and TNF-α
promoters in ChIP assay (data not shown). We did not
observe IL-17 production in more than 50 % of healthy in-
dividuals. Together, these results suggest that TCF-1 binds
to IFN-γ promoter and GZMB enhancer regions and reg-
ulates their expression in FTY720-activated T cells, and
the effect of FTY720 on TNF-α and GMCSF expression
does not depend on TCF-1.
FTY720 downregulates Akt and GSK3 β phosphorylation
and induces epigenetic modification
Increased expression of TCF-1 upon FTY720 treatment
suggests that perhaps FTY720 affects events downstream of
S1P and Wnt signaling pathways. Phosphorylation of Akt,
which is a fundamental step of the sphingosine pathway
[39], induces phosphorylation of other proteins and en-
zymes such as GSK3β [34, 40]. Akt inhibits GSK3 kinase ac-
tivity via phosphorylation of serine 9 (Ser9) in GSK3β,
resulting in its inactivation [41, 42]. GSK3β also plays an
important role in signaling downstream of the Wnt
Fig. 2 FTY720 treatment decreases effector T cell function. a Expression of IFNG and GZMB in in vitro activated T cells from healthy individuals in
the presence or absence of FTY720 as determined by nanostring (n = 6). b Expression of IFNG and GZMB in in vitro activated T cells from healthy
individuals in the presence or absence of FTY720 as determined by qPCR (n = 6). c Expression of IFN-γ and GZMB in in vitro activated T cells from
healthy individuals in the presence or absence of FTY720 as determined by Luminex-based assay (n = 6). d Expression of IFN-γ and GZMB in in
vitro activated T cells from healthy individuals in the presence or absence of FTY720 using flow cytometry (n = 6). *p < 0.05, **p < 0.01, paired
non-parametric t tests
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pathway. Inactivation of GSK3β allows unphosphorylated β-
catenin to accumulate, translocate into the nucleus, and ac-
tivate gene transcription by replacing co-repressor mole-
cules bound to TCF-1 [43, 44]. On the other hand,
decreased levels of phosphorylated/inactive GS3Kβ result in
phosphorylation of β-catenin and its subsequent proteaso-
mal degradation [43]. We performed western blot analysis
to assess the phosphorylation status of Akt at Ser473 and of
GSK3β at Ser9 in FTY720-treated and FTY720-untreated T
cells at different time points. We found decreased phos-
phorylation of Akt at Ser473 (Fig. 4a) and GS3Kβ at Ser9
(Fig. 4b) in T-FTY720 cells compared with T-CTL cells at
all time points. This reduced phosphorylated GS3Kβ
associated with lower levels of β-catenin in T-FTY720 cells
than in T-CTL cells (Fig. 4c). These results indicate that
FTY720 inhibits β-catenin accumulation by reducing Akt-
mediated inactivation/phosphorylation of GSK3β.
In the absence of β-catenin, target genes are silenced by
TCF-1-mediated recruitment of TLE/Groucho proteins
[45]. qPCR analysis showed no differences in the expression
of TLE1, TLE2, and TLE4 but a modest increase in TLE3
expression in T-FTY720 cells compared with T-CTL cells
(Additional file 5: Figure S4). The recruitment of TLE/
Groucho proteins by TCF-1 results in transcriptional sup-
pression of target genes by inducing epigenetic modifica-
tions [46, 47]. To gain further insight into the molecular
Fig. 3 TCF-1 regulates IFNG and GZMB expression. a Binding region of TCF-1 in the promoter of IFNG and enhancer of GZMB. Blue arrows represent
transcription start site. b qPCR analysis of chromatin-immunoprecipitated T cells showing interaction of TCF-1 with the IFNG promoter and GZMB
enhancer region in primary T cells treated with or without FTY720 (n = 7). Data are shown as mean ± SEM. *p < 0.05, paired non-parametric t tests.
c qPCR analysis of TCF7 expression in T cells treated with TCF7 shRNA (sh-TCF7) or negative control (sh-CTL). **p < 0.01, paired non-parametric t tests.
d qPCR analysis of IFNG and GZMB expression in T cells treated with TCF7 shRNA or negative control. **p < 0.01, paired non-parametric t tests.
e Luciferase activity in HEK293T cells transfected with plasmids encoding firefly luciferase downstream of the IFNG promoter region (IFNG-luc), Tbet,
TCF-1, or empty vector control. f Luciferase activity in HEK293T cells transfected with plasmids encoding firefly luciferase downstream of the GZMB
enhancer region (GZMB-luc), TCF-1 or empty vector control. RLU relative light units. Data are shown as mean ± SEM. * **p < 0.01, ***p < 0.001, unpaired
non-parametric t tests
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mechanism by which FTY720-induced TCF-1 regulates
IFN-γ and GZMB expression, we measured methylation
status of histones H3K9 and H3K27 on the IFNG pro-
moter and GZMB enhancer regions after FTY720 treat-
ment using ChIP assay. We observed increased levels of
tri-methylation at H3K9 and H3K27 in the IFNG pro-
moter (Fig. 4d) and GZMB enhancer (Fig. 4e) regions in
T-FTY720 cells compared with T-CTL cells. These results
suggest that FTY720-induced TCF-1 regulates IFN-γ and
GZMB expression by directly binding and inducing re-
pressive chromatin modifications such as tri-methylation
of Lys9 and Lys27 of histone H3.
Expression of TCF7 is decreased in CD4+ T cells from
multiple sclerosis patients
To determine the relevance of TCF-1 in multiple sclerosis
pathogenesis, we first assessed its expression in CD4+ T
cells from multiple sclerosis patients. We found that TCF7
expression was decreased in T cells from untreated RRMS
patients (T-RRMS) compared with T cells from healthy
controls (T-CTL) in both ex vivo isolated (Fig. 5a) and in
vitro-activated (b) T cells. To assess whether FTY720
upregulates TCF7 expression in T cells from RRMS pa-
tients, we activated T-RRMS cells in the presence or ab-
sence of FTY720 and found higher TCF7 expression in
FTY720-treated T-RRMS cells (Fig. 5c).
In order to determine whether the expression of TCF7
is related to multiple sclerosis disease activity, we com-
puted correlations between TCF7 expression in T cells
and clinical parameters such as Expanded Disability Sta-
tus Scale (EDSS) score, disease duration, and number of
relapses 2 years before the date of blood draw. We found
a significant negative correlation (r2 = −0.45, p < 0.05) of
TCF7 expression with EDSS score (Fig. 5d). We did not
Fig. 4 FTY720 downregulates Akt and GSK3β phosphorylation and induces epigenetic modification. a Western blot analysis of cell extracts from
FTY720-treated (T-FTY720) and control T (T-CTL) cells at the indicated time points and analyzed for phosphorylated Akt (p-Akt) and total Akt (tot-Akt).
β-actin served as a loading control. A representative image from one experiment is shown. b Immunoblot of phosphorylated GSK3β (pGSK3β) and
total GSK3β (tot-GSK3β) in cell extracts from T-FTY720 and T-CTL cells at the indicated time points. β-actin served as a loading control. A representative
image from one experiment is shown. c Immunoblot of β-catenin in cell extracts from FTY720 and T-CTL cells at the indicated time points. β-actin
served as a loading control. A representative image from one experiment is shown. d qPCR analysis of chromatin-immunoprecipitated T cells showing
methylation status of H3K9 and H3K27 on the IFNG promoter region (n = 7). Data are shown as mean ± SEM. *p < 0.05, paired non-parametric t tests.
e qPCR analysis of chromatin-immunoprecipitated T cells showing the methylation status of H3K9 and H3K27 on the GZMB promoter region (n = 7).
Data are shown as mean ± SEM. *p < 0.05, paired non-parametric t tests
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find any correlations between TCF7 expression and dis-
ease duration or number of relapses (data not shown).
These results suggest that TCF7 is involved in multiple
sclerosis pathogenesis.
Discussion
FTY720, the first oral drug approved for multiple sclerosis
treatment, is an S1P analog that induces internalization of
S1P receptors on T cells, resulting in lymphocyte sequestra-
tion inside lymph nodes [33]. In addition, FTY720 exhibits
immunomodulatory effects in various immune cell popula-
tions [17, 31, 48–51], including T cells [52, 53], B cells [54],
dendritic cells [55, 56], regulatory T cells [9, 57–60], and
monocytes [56]. FTY720 also regulates the dichotomy
between Th1 and iTregs through S1P1- and mTOR-
dependent pathways [60]. Here, we examined the effect of
FTY720 in human T cells and studied its role in the regula-
tion of pathogenic effector T cell function in MS.
We found that FTY720 treatment increased TCF7 ex-
pression and downregulated IFNG and GZMB expression
in CD4+ T cells. These results are in line with a previous
report which states that FTY720 treatment ameliorates
EAE in mice and decreases IFN-γ and GZMB production
in splenic CD8+ T cells [61].
In mice, TCF-1 expression is linked to regulation of
inflammatory Th1 and Th17 differentiation and develop-
ment of EAE [21, 36, 62]. In this study, we found that
shRNA-mediated knockdown of TCF-1 increases IFNG
and GZMB expressions, indicating that TCF-1 may play a
direct role in IFNG and GZMB expressions. Indeed, ChIP
assay and reporter assay showed that TCF-1 not only dir-
ectly binds to IFNG promoter and GZMB enhancer re-
gions in FTY720-treated T cells but also regulates their
expression. Although we found decreased expression of
IL-17, GMCSF, and TNF-α upon FTY720 treatment, these
cytokines were not followed further in the current study
because IL-17 expression and production was not ob-
served in more than 50 % of healthy individuals and ChIP
assay did not detect binding of TCF-1 to GMCSF or TNF-
α promoter regions (data not shown).
Tbet is a master regulator of Th1 differentiation that
regulates TCF-1 expression through direct interaction
with Bcl-6 [63]. However, we found no differences in the
expression of TBX21 or BCL6 in FTY720-treated T cells
(data not shown), suggesting that a different mechanism
Fig. 5 RRMS T cells show decreased TCF7 expression. a Expression of TCF7 in ex vivo T cells from RRMS patients (T-RRMS, n = 26) and healthy
individuals (T-CTL, n = 21) measured using qPCR. b Expression of TCF7 in activated T-RRMS cells (n = 18) and T-CTL cells (n = 19) measured using
qPCR. c TCF7 expression measured by qPCR in in vitro activated T cells from RRMS patients (n = 10) in the presence or absence of FTY720.
d Correlation between TCF7 expression and EDSS score. *p < 0.05, **p < 0.01, ***p < 0.001, unpaired non-parametric t tests and
Spearman correlation
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was involved in TCF-1 induction in this context. TCF-1
has also been shown to regulate Th2 differentiation
through GATA3 in mice [19]. However, we found no
changes in the expression of GATA3 in human CD4+ T
cells treated with FTY720 (data not shown).
Crosstalk between the sphingosine and Wnt signaling
pathways has been previously shown in osteoblast-like
cells through activation of Akt, GSK3β, and nuclear trans-
location of β-catenin followed by its association with TCF-
1 [34]. In our study, we found decreased phosphorylation
of Akt and GSK3β in FTY720-treated T cells and a reduc-
tion in β-catenin levels upon FTY720 treatment. There-
fore, we speculate that in the presence of FTY720, there is
a decrease in S1P1-mediated phosphorylation of Akt,
which in turn decreases GSK3β phosphorylation. The ac-
tive unphosphorylated GSK3β phosphorylates β-catenin,
resulting in its proteasomal degradation. In the absence of
β-catenin, TCF-1 binds to co-repressors such as TLE/
Groucho family proteins and suppresses the transcription
of target genes such as IFNG and GZMB (Additional file
6: Figure S5).
A recent mouse study shows that selective targeting of
GSK3β in T cells leads to less severe EAE [63]. As the ef-
fect of GSK3β on TCF-1 expression was not investigated
in this study, it is possible that therapeutic targeting of
GSK3β might be linked to increased TCF-1 expression,
which could reduce pathogenic T cell function and alle-
viate EAE symptoms.
In the absence of Wnt signaling, TCF-1 interacts with
transcriptional repressor TLE/Groucho family members
[62, 64], which repress transcription of target genes by in-
ducing epigenetic modification [46, 47]. Acetylation and
methylation on specific lysine residues are important epi-
genetic modifications for gene regulation. Transcription
sites of actively transcribed genes are characterized by the
presence of methylation at H3K4 or acetylation at H3K27,
whereas gene repression is mediated by tri-methylation of
H3K9 or H3K27 [65]. In mice, TCF-1 regulates Th17 dif-
ferentiation through epigenetic changes [20, 21]. Here, we
observed higher levels of histone H3K9 and H3K27 tri-
methylation in the promoter region of IFNG and enhancer
region of GZMB in T-FTY720 cells compared with T-
CTL cells, supporting the hypothesis that FTY720 induces
TCF-1-mediated regulation of IFN-γ and GZMB expres-
sion by chromatin modification. Although the mechanism
of TCF-1 mediated epigenetic modifications was not
addressed in this particular study, it is conceivable that
TCF-1 brings about epigenetic changes by recruiting
histone methyltransferases and other co-repressors such
as TLE in the presence of FTY720.
Multiple sclerosis is the primary cause of non-traumatic
neurologic disability in young adults. IFN-γ producing
and GZMB secreting inflammatory T cells are implicated
in its pathogenesis [3–6, 10, 66–68]. However, the
regulatory mechanisms controlling pathogenic effector T
cell function in multiple sclerosis are not completely
understood. We found significantly decreased TCF7 ex-
pression in T cells from relapsing-remitting multiple scler-
osis patients compared with those from healthy
individuals and the treatment with FTY720 increased
TCF-1 expression in both groups. Moreover, TCF7 expres-
sion in T cells is inversely correlated to disease disability
as measured by EDSS.
Conclusions
We observed that TCF-1 expression is reduced in T cells
from relapsing-remitting patients. FTY720 treatment in-
creases TCF-1 expression in CD4+ T cells from multiple
sclerosis patients as well as from healthy individuals. The
modulation of the sphingosine pathway is able to interfere
with the downstream signaling of the Wnt pathway by
reducing the availability of β-catenin and subsequently
repressing the transcription of target genes. FTY720-
induced TCF-1 expression in CD4+ T cells downregulates
the pathogenic cytokines IFN-γ and GZMB by binding to
their promoter/enhancer region and mediating epigenetic
modifications. We also showed that TCF7 expression
negatively correlates with EDSS score in multiple sclerosis
patients, suggesting a possible role of TCF-1 in the patho-
genesis of multiple sclerosis. Together, our results reveal a
previously unknown mechanism by which FTY720 func-
tions in multiple sclerosis, and suggests that targeting
TCF-1 signaling in CD4+ T cells could be a potential
treatment strategy for multiple sclerosis.
Additional files
Additional file 1: Table S1. Multiple sclerosis patient characteristics. All
multiple sclerosis patients had relapsing-remitting disease courses.
s.d. = standard deviation.
Additional file 2: Figure S1. Flow cytometry analysis of CD4+ and
naïve CD4+ T cells from multiple sclerosis patients before and after
3 months of treatment with fingolimod. BL = baseline, RV = revisit (n = 8).
*p < 0.05, **p < 0.01, paired non-parametric t tests.
Additional file 3: Figure S2. FTY720 increases TCF7 expression in T
cells. Expression of TCF7 in in vitro activated T cells from healthy
individuals in the presence or absence of FTY720, natalizumab (T-Ty), or
interferon beta (T-IFN beta). Data are shown as mean ± SEM. *p < 0.05,
ns = not significant, paired non-parametric t tests.
Additional file 4: Figure S3. FTY720 reduces expression of
pro-inflammatory cytokines. A) Expression of IL-17 (n= 9), GMCSF (n= 24),
and TNFα (n= 24) in in vitro activated T cells from healthy individuals in the
presence or absence of FTY720 using Luminex-based assay. (Note: IL-17
expression could not be measured in 15 healthy individuals.) B) Viabity
staining of in vitro-activated T cells in the presence or absence of FTY720.
Data are shown as mean ± SEM. *p< 0.05, ***p< 0.001, ns = not significant,
paired non-parametric t tests. C) Binding region of TCF-1 in the promoter of
IL17, CSF2, and TNF-α. Blue arrows represent transcription start site.
Additional file 5: Figure S4. Effect of FTY720 on expression of TLE
family proteins. Expression of TLE1, TLE2, TLE3, and TLE4 using qPCR
(n = 8). Data are shown as mean ± SEM. *p < 0.05, ns = not significant,
paired non-parametric t tests.
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Additional file 6: Figure S5. Proposed model of interaction between
S1P1 and Wnt signaling pathways. A) S1P1 receptor activation induces Akt
phosphorylation, which in turn induces phosphorylation of GSK3β.
Phosphorylation of GSK3β at Ser9 leads to its inactivation, which allows
unphosphorylated β-catenin to accumulate and translocate into the
nucleus, where it binds to TCF-1 and induces transcription of target
genes. B) In the presence of FTY720, the S1P1 receptor is downregulated,
and less Akt is phosphorylated. Inactive Akt cannot phosphorylate GSK3β,
which leads to the ability of GSK3β to phosphorylate β-catenin and thus,
induce its degradation. In the absence of β-catenin, TCF-1 binds to
co-repressors, such as TLE/Groucho family proteins, and represses the
transcription of target genes.
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